Gilead Sciences

By and large, the number of shares short in the leading biotech and emerging pharmaceutical stocks shrank between the June 15 and June 30 settlement dates. The trend was particularly noticeable in Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Gilead Sciences, Inc. (NASDAQ: GILD), which saw...

Some of the biggest swings in short interest among the leading biotechs and emerging pharmaceuticals between the May 29 and June 15 settlement dates happened to Amgen, Inc. (NASDAQ: AMGN), Gilead Sciences, Inc. (NASDAQ: GILD) and Illumina, Inc. (NASDAQ: ILMN). Let's take a quick look at how these...

While short interest moves in most of the leading biotechs and emerging pharmaceuticals were mild between the May 15 and May 29 settlement dates, short sellers fled from some of the biggest players in the field. Biogen Inc (NASDAQ: BIIB), Celgene Corporation (NASDAQ: CELG) and Gilead Sciences, Inc...

Bernstein analyst Geoffrey Porges said it's time for Gilead Sciences, Inc. (NASDAQ: GILD) to continue the biotech M&A with a bid for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Porges noted that many investors "remain heavily exposed to mid and large cap biotech stocks"...

Short interest among leading biotechs and emerging pharmaceuticals increased nearly all across the board between February 13 and February 27. Leading the trend were BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Celgene Corporation (NASDAQ: CELG) and Vertex Pharmaceuticals Incorporated (NASDAQ:...

By and large, short interest among the leading biotechs and emerging pharmaceuticals reversed course and rose again between the January 30 and February 13 settlement dates. Leading that trend were Amgen, Inc. (NASDAQ: AMGN), Juno Therapeutics Inc (NASDAQ: JUNO) and Vertex Pharmaceuticals...

Weak earnings and outlooks have recently prompted some insiders to purchase shares, even as markets take aim for new record highs. Gilead Sciences, Atlas Energy and Intrexon were among those that have seen significant insider buys. Insiders may sell shares for any number of reasons, but...

By and large, short interest among the leading biotechs and emerging pharmaceuticals dwindled between the January 15 and January 30 settlement dates. Leading that trend were Amgen, Inc. (NASDAQ: AMGN), Celgene Corporation (NASDAQ: CELG) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Here...

It is clear that the mixed earnings results seen so far have contributed to the volatility in the markets throughout January. While many of the market movers have already shared their most recent quarterly results, there are plenty more on tap as February gets started. Among the most...

U.S. markets began the week on a negative note after markets sold off in the final two hours of trading on no major news catalyst. The S&P 500 fell through its 200-day moving average of 1,905, a key technical level for fundamental investors and traders. The last time the index broke its 200...

Biotechs continue to prove volatile this year. While Gilead Sciences, Inc. (NASDAQ: GILD) and Illumina, Inc. (NASDAQ: ILMN) saw a sizable drops in short interest between the September 15 and September 30 settlement dates, short sellers loaded up on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX...

When it comes to the search for Ebola treatments, names like BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), Chimerix Inc (NASDAQ: CMRX), Sarepta Therapeutics Inc (NASDAQ: SRPT) and Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR) have cropped up frequently. Could these or other biotech companies...

U.S. stocks rose as many questions remain unanswered following the crash of MH17 over the unstable region of Donetsk in Ukraine. U.S. intelligence sources speculated the plane was brought down by a ground-to-air missile but cannot confirm who was responsible. Investors appear to focus on...

U.S. stocks rose ahead of next week's busy earnings schedule, but still finished lower for the week. On Tuesday, Yahoo! and Intel kick off earnings in the tech sector with eBay following on Wednesday. Investors will also see results from Citigroup, Goldman Sachs and JPMorgan Chase in the...